Table 7.
Review of previous studies following first- to third-line chemotherapy for patients with advanced non-small-cell lung cancer
| Study | Country | Patients | Study design | Study periods | Chemotherapy
|
||
|---|---|---|---|---|---|---|---|
| First-line | Second-line | Third-line | |||||
|
| |||||||
| Efficacy, N | Efficacy, N (%)a | Efficacy, N (%)a | |||||
| Murillo and Koeller9 | USA | NSCLC, stage IIIB–IV | Ten community oncology clinics, retro, cross-sectional | 2000–2003 | 417 | 232 (56%) | 110 (28%) |
| Girard et al10 | France | NSCLC, stage IIIB–IV | A university hospital, single institution, retro | January 2000–December 2006, followed until December 2008 | 613 | 338 (55%) | 173 (28%) RR 6% DCR 36% mOS 5.8 months |
| Park et al11 | South Korea | NSCLC, stage IIIB–IV (including 26.8% SQ) | A university hospital, single institution, retro | March 2003–February 2007 | 82 | 49 (59.8%) | 33 (40.2%) |
| Zietemann and Duell14 | Germany | NSCLC, stage IIIB wet–IV (including 27% SQ) | A hospital for chest disease, single institution, pros | January 2003–July 2007, followed until August 2010 | 406 RR 33% DCR 64% mPFS 146 days mOS 268 days |
213 (52%) RR 13% DCR 41% mPFS 49 days mOS 139 days |
110 (27%) RR 8% DCR 39% mPFS 51 days mOS 115 days |
| Gridelli et al8 | Italy | NSCLC, stage IIIB–IV (including 28% SQ) | 74 multicentered, 1-year longitudinal observation, pros | January 2007–March 2008 | 790 mOS 9.1 months |
275 (35%) | 58 (7.3%) |
| Younes et al13 | Brazil | Stage IV NSCLC SQ 30.5% | Two hospitals, retro | 1990–2008 | 57.9% RR 38.7% DCR 50% mOS 8 months |
23.4% RR 10.4% DCR 30% |
8% RR 7% DCR 29.4% |
| Eccles et al12 | UK | NSCLC, stage IIIB–IV (including 28% SQ) | Two hospitals, retro | January 2007–December 2008, followed until March 2010 | 110 RR 44% DCR 58% TTP 5 months |
50 (45%) RR 12% DCR 38% TTP 3 months |
10 (9%) RR 20% DCR 60% TTP 3.75 months |
| Asahina et al7 | Japan | NSCLC, stage IIB, IV, and recurrent (including 14.4% SQ) | A cancer center, single institution, retro | July 2002–June 2006 | 599 RR 35.7% DCR 64.8% mOS 15.3 months |
415 (69.3%) RR 23.5% DCR 44.4% mOS 12.8 months |
230 (38.4%) RR 17.0% DCR 34.4% mOS 12.0 months |
| Reinmuth et al6 | Germany | NSCLC, stage IV (including 15.9% SQ) | A university hospital, single institution, retro | January 2004–December 2006, followed until December 2011 | 352 RR 30.7% DCR 59.7% mOS 7.6 months |
183 (52%) RR 14.8% DCR 46.5% mOS 6.2 months |
97 (27.6%) RR 12.4% DCR 36.1% mOS 5.2 months |
| Moldvay et al15 | Hungary | Lung cancer | Based on national inpatient and prescription database, retro | January 2008–December 2010 | 12,326 | 3,791 (31%) | 1,174 (10%) |
| Davis et al2 | USA | SQ, stage IV | Based on Medicare database, retro | January 2001–December 2009 | 7,029 | 3,405 (48%) | 1,713 (24%) |
| Our study | Japan | SQ, stage IIIB and IV | An acute-care hospital, single institution, retro | June 2007–March 2015, followed until November 2015 | 103 RR 42.7% DCR 64.1% mPFS 134 days mOS 381 days |
63 (65%) RR 6.3% DCR 44.4% mPFS 90 days mOS 205 days |
32 (34%) RR 3.1% DCR 28.1% mPFS 56 days mOS 167 days |
Note:
a
Percentage of patients receiving second- and third-line chemotherapy among patients receiving first-line chemotherapy.
Abbreviations: DCR, disease control rate; mOS, median overall survival; mPFS, median progression-free survival; NSCLC, non-small-cell lung cancer; pros, prospective study; retro, retrospective study; RR, response rate; SQ, squamous cell carcinoma; TTP, median time to progression.